Detalhe da pesquisa
1.
Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
J Med Virol
; 96(4): e29609, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38647051
2.
Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
J Infect Dis
; 226(4): 576-584, 2022 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32726419
4.
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation.
Antivir Ther
; 28(5): 13596535231195431, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657421
5.
Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
J Med Econ
; 25(1): 367-380, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240904
6.
Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
Antiviral Res
; 172: 104616, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31568799
7.
Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.
Orphanet J Rare Dis
; 12(1): 117, 2017 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28651568